Study finds large gap in breast cancer treatment recommendations for patients aged 70 vs 69

Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale

Ian E. Krop was named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs for Yale Cancer Center and Smilow Cancer Hospital.

June 18, 2026

Vol.52 No.24

In Brief

Mina Sedrak and Vijaya Raj Bhatt to co-lead Alliance’s committee on cancer care for older adults

Mina Sedrak, director of the UCLA Center for Cancer and Aging and director of Cancer Control and Survivorship Research at the UCLA Health Jonsson Comprehensive Cancer Center, and Vijaya Raj Bhatt professor and medical director of the Leukemia Program at the University of Nebraska Medical Center, were selected to serve as co-chairs of the Cancer in the Older Adult Committee for The Alliance for Clinical Trials in Oncology.

June 05, 2026

Vol.52 No.22

Clinical Roundup

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.

June 05, 2026

Vol.52 No.22

Drugs & Targets

FDA approves Enhertu in HER2+ early breast cancer for both neoadjuvant and adjuvant treatment

FDA approved Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, respectively.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Stage 4 breast cancer has increased in incidence and proportion over the last decade

Researchers found that cases of stage 4 breast cancer are increasing both in incidence and as a proportion of all breast cancer diagnoses, according to findings from an observational study.

May 15, 2026

Vol.52 No.19

Drugs & Targets

FDA clears AI digital pathology risk stratification tool in breast cancer

FDA cleared ArteraAI Breast, a multimodal AI-based prognostic and predictive cancer test, for use in patients with early-stage, hormone receptor-positive HER2-negative invasive breast cancer.

May 15, 2026

Vol.52 No.19

Study finds large gap in breast cancer treatment recommendations for patients aged 70 vs 69

YOU MAY BE INTERESTED IN

Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale

Mina Sedrak and Vijaya Raj Bhatt to co-lead Alliance’s committee on cancer care for older adults

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

FDA approves Enhertu in HER2+ early breast cancer for both neoadjuvant and adjuvant treatment

Stage 4 breast cancer has increased in incidence and proportion over the last decade

FDA clears AI digital pathology risk stratification tool in breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login